Name
LAP3 Human
Cat. No.
MAG-3525
Tag/Conjugates
His
Source
Escherichia Coli.
Shipped
Shipped with Ice Packs
Description
LAP3 Human Recombinant produced in E.Coli is a single,non-glycosylated polypeptide chain containing 539 amino acids (1-519 a.a) and having a molecular mass of 58.3kDa.
Introduction
Leucine Aminopeptidase 3 also known as LAP3 is a member of the peptidase
M17 family. LAP3 is implicated in the processing as well as regular turnover of
intracellular proteins. LAP3 catalyzes the removal of unsubstituted N-terminal
amino acids from different peptides. LAP3
is responsible of releasing an N-terminal amino acid, Xaa-|-Yaa-, in which Xaa
is preferably Leu, but could be other amino acids including Pro although not
Arg or Lys, and Yaa may be Pro. Amino acid amides and methyl esters are as well
readily hydrolyzed; however rates on arylamides are exceedingly low.
Purification Method
/
Physical Appearance
Sterile Filtered colorless solution.
Formulation
LAP3 protein solution (0.5mg/ml) containing 20mM
Tris-HCl(pH8.5), 50% glycerol, 5mM DTT and 1mM EDTA.
Stability
Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles.
Purity
Greater than 85% as determined by SDS-PAGE.
Biological Activity
/
Safety Data Sheet
SDS
Usage
Mabioway's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Synonyms
Leucine Aminopeptidase 3, Peptidase S, PEPS, Proline
Aminopeptidase, Leucyl Aminopeptidase, Prolyl
Aminopeptidase, EC 3.4.11.1, LAP-3, LAPEP, Epididymis Secretory Protein Li 106,
Cytosol Aminopeptidase, EC 3.4.11.5, HEL-S-106, EC 3.4.11, LAP, Cytosol
aminopeptidase, Leucine aminopeptidase 3, Leucyl aminopeptidase, Proline
aminopeptidase, Prolyl aminopeptidase.
Amino acid sequence
MGSSHHHHHH SSGLVPRGSH MFLLPLPAAG RVVVRRLAVR RFGSRSLSTA DMTKGLVLGI YSKEKEDDVP QFTSAGENFD KLLAGKLRET
LNISGPPLKA GKTRTFYGLH QDFPSVVLVG LGKKAAGIDE QENWHEGKEN IRAAVAAGCR QIQDLELSSV
EVDPCGDAQA AAEGAVLGLY EYDDLKQKKK MAVSAKLYGS GDQEAWQKGV LFASGQNLAR QLMETPANEM
TPTRFAEIIE KNLKSASSKT EVHIRPKSWI EEQAMGSFLS VAKGSDEPPV FLEIHYKGSP NANEPPLVFV
GKGITFDSGG ISIKASANMD LMRADMGGAA TICSAIVSAA KLNLPINIIG LAPLCENMPS GKANKPGDVV
RAKNGKTIQV DNTDAEGRLI LADALCYAHT FNPKVILNAA TLTGAMDVAL GSGATGVFTN SSWLWNKLFE
ASIETGDRVW RMPLFEHYTR QVVDCQLADV NNIGKYRSAG ACTAAAFLKE FVTHPKWAHL DIAGVMTNKD
EVPYLRKGMT GRPTRTLIEF LLRFSQDNA.
Background
/
